2022
KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves
Zhao J, Syn N, Tan B, Yap D, Teo C, Chan Y, Sundar R. KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves. BMC Medical Research Methodology 2022, 22: 93. PMID: 35369867, PMCID: PMC8978435, DOI: 10.1186/s12874-022-01567-z.Peer-Reviewed Original ResearchConceptsMonte Carlo simulationsLimits of errorSubgroup survival dataCarlo simulationsSurvival dataKaplan-MeierKaplan-Meier survival curvesExtensive Monte Carlo simulationsOriginal survival dataFollow-up timeCox proportional hazards modelsSubgroups of clinical interestPublished Kaplan-Meier survival curvesMarginal Cox proportional hazards modelsProportional hazards modelMatched patientsSecondary data analysisSystematic errorsSurvival curvesProportion of missing dataHazards modelClinical interestPatientsPrimary manuscriptsKM plots
2021
Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma
Zhao J, Yap D, Chan Y, Tan B, Teo C, Syn N, Smyth E, Soon Y, Sundar R. Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. Journal Of Clinical Oncology 2021, 40: 392-402. PMID: 34860570, DOI: 10.1200/jco.21.01862.Peer-Reviewed Original ResearchConceptsProgrammed death-ligand 1Combined positive scoreImmune checkpoint inhibitorsKEYNOTE-062First-line treatmentCheckMate-649Checkpoint inhibitorsEsophageal adenocarcinomaKaplan-MeierEstimate time-to-event outcomesFirst-line immune checkpoint inhibitorsPD-L1 combined positive scoreProgrammed death ligand 1 subgroupsPatients treated with pembrolizumabPD-L1-expressing tumorsRandomized phase III trialEfficacy of ICIsPD-L1 subgroupsProgression-free survivalDeath-ligand 1Phase III trialsUS Food and Drug AdministrationPrimary manuscriptsFood and Drug AdministrationCPS-1